Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29635976 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL1922779 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| SCHEMBL18122612 | 0.91 | CHRM3 (0.83) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6017543 | 0.88 | CHRM3 (0.77) | CHRM3CHRM2CHRM1 | |
| SCHEMBL27692690 | 0.87 | CHRM3 (0.77) | CHRM3CHRM2CHRM1 | |
| SCHEMBL10015123 | 0.86 | CHRM3 (0.76) | CHRM3 | |
| SCHEMBL828900 | 0.85 | CHRM3 (0.74) | CHRM3CHRM2CHRM1 | |
| SCHEMBL19066180 | 0.85 | CHRM3 (0.73) | CHRM3CHRM2CHRM1 | |
| SCHEMBL18229054 | 0.84 | CHRM3 (0.72) | CHRM3CHRM2CHRM1 | |
| SCHEMBL18115407 | 0.82 | CHRM3 (0.69) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-25 | — | — | US | claimed |
| CN-114573500-B | Preparation method of raffinancin intermediate | 扬州中宝药业股份有限公司 | 2024-02-20 | — | — | CN | claimed |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-29 | — | — | US | claimed |
| CN-114573500-A | Preparation method of lefenacin intermediate | 扬州中宝药业股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-113121412-A | Preparation method of lefenacin intermediate | 扬州中宝药业股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-112830890-A | Preparation method of lefenacin intermediate and lefenacin | 上海谷森医药有限公司 | 2021-05-25 | — | — | CN | claimed |
| US-20250136550-A1 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | THERAVANCE BIOPHARMA R&D IP, LLC | 2025-05-01 | — | — | US | disclosed |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240327352-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE | MSN LABORATORIES PRIVATE LTD, R&D CENTER (IN) | 2024-10-03 | — | — | US | disclosed |
| CN-118401497-A | Crystalline acetone solvate of Lei Fen nacin | 医药化学公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-114573500-B | Preparation method of raffinancin intermediate | 扬州中宝药业股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-114573500-B | Preparation method of raffinancin intermediate | 扬州中宝药业股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-113563255-B | Preparation method of remifloxacin intermediate | 成都倍特药业股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-1082289-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999066944-A9 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999064043-A9 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999066944-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999064043-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064032-A1 | COMBINATORIAL SYNTHESIS OF MULTIBINDING LIBRARIES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0747355-A1 | NOVEL CARBAMATE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136550-A1 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | CYP4B1, KDM4B, CYP3A4 | CHRM3 1755/4885CHRM2 2542/4885CHRM1 1997/4885 |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885CHRM1 2/4885 |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885CHRM1 2/4885 |
| US-20240327352-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE | CYP4B1, CYP1B1, KDM4B | CHRM3 357/4885CHRM2 207/4885CHRM1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.